EVO301 / AprilBio, Evommune - LARVOL DELTA

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress (Businesswire)

Late-breaking abstract • P2a data • Atopic Dermatitis

Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis. (EADV 2026) - No abstract available

Clinical • P2a data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL18

Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis. (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • P2a data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL18

'We continue to work towards bringing meaningful clinical benefit to AD patients, and importantly, EVO301, our IL-18BP fusion protein, which recently generated positive Phase 2a proof-of-concept data, will enter a Phase 2b trial planned for mid-2027' (Businesswire)

New P2b trial • Atopic Dermatitis

AprilBio(397030) will additionally transfer materials needed for the clinical trials and production of the autoinflammatory disease drug candidate "EVO301," which it out-licensed to U.S.-based Evommune, and will receive about 600 million won. (Chosun Biz) - "The total contract amount is $431,28.17, which is about 599.17 million won based on the exchange rate that day (1,393 won per dollar). That equals 27.6% of AprilBio's sales last year...Under the agreement, AprilBio will hand over to Evommune 325 vials of a master cell bank (MCB) and 162 vials of a reference standard needed to produce EVO301. It will also transfer 80 vials of drug product, but that is without charge....The contract takes effect on the 24th, and payment is to be made within 30 days of invoice issuance."

Licensing / partnership • Atopic Dermatitis • Immunology • Rheumatoid Arthritis

Evaluating Additional Indication Expansion Opportunities (Businesswire) - "The Company continues to evaluate additional indications for EVO301, including ulcerative colitis and certain cardiovascular-related inflammatory conditions, as potential new Phase 2 clinical trials."

Pipeline update • Cardiovascular • Inflammation • Ulcerative Colitis

EVO301 – Injectable IL-18 Binding Protein Fusion Protein Program (Businesswire) - "Full Results from Positive Phase 2a Trial in AD to be Presented at Upcoming Medical Conference...Phase 2b AD Trial to Initiate in mid-2027: The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three subcutaneous dosing regimens of EVO301 tested over a 16-week treatment period."

New P2b trial • P2a data • Atopic Dermatitis • Immunology

AprilBio to be acquired by chemical group TKG in $225 mil. deal (Korea Biomedical Review) - "Under the terms of the offering, TKG Huchems and IMM Startup Venture Fund No. 2, a venture fund managed by IMM Investment, will receive 155 billion won in voting convertible preferred shares, giving TKG effective management control. IMM Asset Management Co. and IMM Scale-up Bio Fund No. 1 will receive 141.8 billion won in ordinary shares priced at 34,620 won each and 50 billion won in nonvoting convertible preferred shares. New shares are scheduled for issuance July 24."

M&A • Atopic Dermatitis • Immunology

AprilBio secures 430 billion won to speed R&D while keeping tech‑out model (Chosun Biz) - "A representative case is APB-A1, a thyroid eye disease treatment candidate out-licensed in 2021 to Denmark's Lundbeck for about 560 billion won. It is currently in phase 2 clinical trials. In 2024, it transferred APB-R3, a candidate for autoinflammatory diseases, to U.S.-based Evoimmune for about 650 billion won. This molecule is being developed as an atopic dermatitis treatment..."

Financing • Atopic Dermatitis • Immunology • Thyroid Eye Disease

AprilBio to pitch REMAP platform at BIO 2026 as licensed assets show clinical progress (Korea Biomedical Review) - "Evommune is expected to present the full phase 2a results at the European Academy of Dermatology and Venereology (EADV) Congress in September. The company is also expected to pursue further development, including transitioning to a subcutaneous formulation and optimizing doses in later-stage trials."

P2a data • Pipeline update • Atopic Dermatitis • Immunology

EVO301: a potent, novel IL18 inhibiting biologic demonstrating robust preclinical data for the treatment of atopic dermatitis (SID 2026) - "In efficacy studies, EVO301 demonstrated the ability to improve disease parameters in the chronic oxazolone dermatitis model. In conclusion, targeting IL18 with therapeutics such as EVO301, may demonstrate efficacy in heterogenous inflammatory conditions such as atopic dermatitis."

Late-breaking abstract • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL18 • IL18BP

EVO301 – Injectable IL-18 Binding Protein Fusion Protein (Yahoo Finance UK) - "Evommune has completed work on a high-concentration subcutaneous formulation of EVO301 and manufacturing has been initiated...The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three dosing regimens of EVO301 tested over a 16-week treatment period, with a planned trial start in mid-2027 following completion of standard scale-up and toxicology activities...The Company continues to evaluate additional indications for EVO301, including ulcerative colitis, certain cardiovascular-related inflammatory conditions and food allergy, as potential new Phase 2 clinical trials....Upcoming Preclinical Data Presentation at Society for Investigative Dermatology (SID) 2026 Annual Meeting."

Commercial • New P2b trial • Preclinical • Allergy • Atopic Dermatitis • Cardiovascular • Ulcerative Colitis

Next Steps (Businesswire) - "The Company continues to advance planning for a Phase 2b dose‑ranging trial in patients with AD, using a subcutaneous formulation of EVO301. The Company is also evaluating potential additional indications for EVO301, including ulcerative colitis."

Clinical • New P2b trial • Atopic Dermatitis • Ulcerative Colitis

'Efficacy results in patients from the phase 2a trial of APB-R3 and the phase 1b trial of APB-A1 are expected to be announced in the first half.' (Chosun Biz)

P1 data • P2a data • Atopic Dermatitis • Immunology

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis (Businesswire) - "EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo; 33% placebo-adjusted improvement in EASI at week 12; 23% of EVO301 patients achieved IGA 0/1 at week 12...The trial met its primary endpoint; a Bayesian success criterion related to the difference between active and placebo in the percent improvement in baseline in the Eczema Area and Severity Index (EASI). While the success criterion required at least 75% of the posterior distribution to be an improvement of at least 8% over placebo, the results of the study demonstrated 99.8% of the posterior distribution met that threshold....Full results from the Phase 2a trial will be presented at a future scientific conference."

P2a data • Atopic Dermatitis

Pipeline Highlights: EVO301 (Businesswire) - "The Company initiated a Phase 2 trial (n=60) of EVO301 in adult patients with moderate-to-severe AD in March 2025. This trial is fully enrolled, and the Company expects to report top-line results in the first half of 2026."

P2a data • Atopic Dermatitis

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=71 | Completed | Sponsor: Evommune, Inc. | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model (ISDS 2025) - "Finally, EVO301 demonstrated the ability to improve disease parameters in the chronic oxazolone dermatitis model. In conclusion, EVO301 is a novel biological therapy targeting the IL18 pathway and may provide a unique mechanism of action to treat inflammatory diseases such as atopic dermatitis."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL18BP

AprilBio's key clinical trial results are expected to be announced in the first half of next year, drawing attention. "Short-term R&D momentum is evident." [Google translation] (Nate) - "Interim results are scheduled to be shared internally by the end of September, with limited external disclosure. Due to the clinical nature of the study, the degree of ocular protrusion can be visually confirmed. The plan is to announce final results from Phase 1b in the first half of next year, followed by Phase 2 for TED and additional indications....Another partner, Evomune, is conducting a Phase 2a trial of APB-R3 (IL-18BP-SAFA) in atopic dermatitis involving 60 subjects, with a target completion date of December. Results, including EASI scores and pruritus indices at week 12, are expected to be announced in the first quarter of next year."

Enrollment status • P1 data • P2a data • Atopic Dermatitis • Thyroid Eye Disease

"Stable cash flow expected due to milestone payments from partner companies' additional clinical trials." [Google translation] (Nate) - "'With the milestone receipt (KRW 20 billion) for the start of phase 2 clinical trials for APB-A1 and phase 2b for APB-R3 next year...'"

New P2 trial • Atopic Dermatitis • Immunology • Rheumatoid Arthritis • Thyroid Eye Disease

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Evommune, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

April Bio, "APB-R3, MASH treatment potential proven" [Google translation] (HIT News) - "AprilBio...announced on the 21st that the research results showing that the company's new drug candidate 'APB-R3' was effective in treating metabolic abnormality-related steatohepatitis (MASH) were published in the international academic journal 'Cell Reports Medicine (IF 11.7)'....According to the research results, IL-18, an inflammatory factor, was highly expressed in MASH patients and model animals, and liver inflammation and fibrosis were further aggravated in mice deficient in IL-18BP."

Preclinical

Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. (PubMed, Cell Rep Med) - "APB-R3 significantly improves MASH in reducing fibrosis and inflammation and inhibits hepatic stellate cell activation via the cGMP pathway. This study proposes that abrogation of IL-18 signaling by boosting IL-18BP can strongly inhibit the development of MASH-induced fibrosis, and our engineered IL-18BP biologics can become a promising therapeutic candidate for curing MASH."

Journal • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • CD4 • IFNG • IL18

Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis (PRNewswire) - "Evommune...announced the enrollment of the first patient in a Phase 2 trial of EVO301 in adult patients with moderate-to-severe AD....The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. The primary objective of this study is to characterize the efficacy of EVO301, assessed by the percentage change in EASI from baseline at week 12."

Enrollment open • Atopic Dermatitis

April Bio's technology transfer candidate substance 'APB-R3' global phase 2 trial begins in earnest [Google translation] (News1 Korea) - "The global phase 2 clinical trial of 'APB-R3', a candidate substance for the treatment of autoinflammatory diseases for which April Bio...transferred technology to the US new drug developer Evommune, has begun in earnest. Evommune began recruiting clinical patients about two months after starting phase 2 clinical trials last year. The first patient administration is expected to take place soon...According to industry sources on the 5th, Evommune began recruiting patients for the phase 2 clinical trial of 'EVO301' targeting moderate to severe atopic dermatitis patients on the 24th of last month...The target number of patients is 60. EVO301 is the name of the candidate substance that changed after April Bio's APB-R3 was transferred to Evommune....April Bio will receive a milestone payment upon administration of the first patient. However, the size of the milestone payment has not been disclosed."

Commercial • Trial status • Atopic Dermatitis